These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3757406)

  • 1. Disposition of vancomycin during hemofiltration.
    Matzke GR; O'Connell MB; Collins AJ; Keshaviah PR
    Clin Pharmacol Ther; 1986 Oct; 40(4):425-30. PubMed ID: 3757406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin disposition during continuous arteriovenous hemofiltration.
    Dupuis RE; Matzke GR; Maddux FW; O'Neil MG
    Clin Pharm; 1989 May; 8(5):371-4. PubMed ID: 2743733
    [No Abstract]   [Full Text] [Related]  

  • 3. Vancomycin clearance in high-volume venovenous hemofiltration.
    Paciullo CA; Harned KC; Davis GA; Connor MJ; Winstead PS
    Ann Pharmacother; 2013 Mar; 47(3):e14. PubMed ID: 23404801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Extracorporeal Membrane Oxygenation on the New Vancomycin Dosing Regimen in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration.
    Yang CJ; Wu CW; Wu CC
    Ther Drug Monit; 2018 Jun; 40(3):310-314. PubMed ID: 29746432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of vancomycin in patients with various degrees of renal function.
    Matzke GR; McGory RW; Halstenson CE; Keane WF
    Antimicrob Agents Chemother; 1984 Apr; 25(4):433-7. PubMed ID: 6732213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin and tobramycin clearance in an infant during continuous hemofiltration.
    Armstrong DK; Hidalgo HA; Eldadah M
    Ann Pharmacother; 1993 Feb; 27(2):224-7. PubMed ID: 8439703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased vancomycin elimination with continuous hemofiltration.
    Lau AH; Kronfol NO; John E
    ASAIO Trans; 1987; 33(3):772-4. PubMed ID: 3676016
    [No Abstract]   [Full Text] [Related]  

  • 8. Elimination of vancomycin during hemofiltration.
    Rawer P; Seim KE
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):529-31. PubMed ID: 2504595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients.
    Zarowitz BJ; Anandan JV; Dumler F; Jayashankar J; Levin N
    J Clin Pharmacol; 1986; 26(8):686-9. PubMed ID: 3793961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration.
    De Bock V; Verbeelen D; Maes V; Sennesael J
    Nephrol Dial Transplant; 1989; 4(7):635-9. PubMed ID: 2510061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of vancomycin by continuous arteriovenous hemofiltration.
    Lau AH; John E
    Child Nephrol Urol; 1988-1989; 9(4):232-5. PubMed ID: 3255486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of vancomycin during continuous arteriovenous hemodiafiltration.
    Bellomo R; Ernest D; Parkin G; Boyce N
    Crit Care Med; 1990 Feb; 18(2):181-3. PubMed ID: 2298011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance.
    Macias WL; Mueller BA; Scarim SK
    Clin Pharmacol Ther; 1991 Dec; 50(6):688-94. PubMed ID: 1752113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients.
    Petejova N; Martinek A; Zahalkova J; Duricova J; Brozmannova H; Urbanek K; Grundmann M; Plasek J; Kacirova I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):65-72. PubMed ID: 23132513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Individualized vancomycin dosing for a patient diagnosed as severe acute pancreatitis with concurrent extracorporeal membrane oxygenation and continuous veno-venous hemofiltration therapy: a case report].
    He N; Yan YY; Ying YQ; Yi M; Yao GQ; Ge QG; Zhai SD
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):915-920. PubMed ID: 30337758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients.
    Saima S; Echizen H; Yoshimoto K; Ishizaki T
    J Clin Pharmacol; 1990 Feb; 30(2):159-62. PubMed ID: 2312768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.
    Moellering RC; Krogstad DJ; Greenblatt DJ
    Ann Intern Med; 1981 Mar; 94(3):343-6. PubMed ID: 6101256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin pharmacokinetics in critically ill patients.
    Garaud JJ; Regnier B; Inglebert F; Faurisson F; Bauchet J; Vachon F
    J Antimicrob Chemother; 1984 Dec; 14 Suppl D():53-7. PubMed ID: 6520066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin elimination in patients with burn injury.
    Brater DC; Bawdon RE; Anderson SA; Purdue GF; Hunt JL
    Clin Pharmacol Ther; 1986 Jun; 39(6):631-4. PubMed ID: 3709027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin disposition: the importance of age.
    Cutler NR; Narang PK; Lesko LJ; Ninos M; Power M
    Clin Pharmacol Ther; 1984 Dec; 36(6):803-10. PubMed ID: 6499360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.